On International Day of Women and Girls in Science, 11 February, EASL honours the many women making waves in our field of hepatology. As highlighted by the UN, both science and gender equality are vital for us to achieve the…
9 February 2021 By end-January 2021, COVID-19, the systemic disease caused by the pandemic spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), accounted for 2.2 million deaths worldwide and for 100 million individuals infected, according to estimates from the…
Digital Liver Cancer Summit 2021: New follow-up data from a landmark study of liver cancer patients treated with a combination of atezolizumab and bevacizumab has shown the longest ever survival time in a frontline phase 3 trial of systemic therapy…
Digital Liver Cancer Summit 2021: A global survey assessing the impact of COVID-19 on liver cancer has revealed delays in the screening, diagnosis, and treatment of the disease, with experts issuing stark warnings on liver cancer survival rates. February 5,…
4 February 2021 The month of February brings together several key actions to tackle cancer globally, and EASL is focussing particularly on the global threat of liver cancer. EASL draws on all these initiatives, in alignment with its goals embedded…
Digital Liver Cancer Summit 2021: As the latest data suggests, liver cancer is now the third-most deadly cancer in the world, claiming nearly 1 million lives in 2020, the liver community takes robust action to tackle the burden posed by…
In memoriam: Prof. Wolfgang Gerok (1926–2021) and Prof. Roberto Groszmann (1939–2021) 20 January 2021 EASL is greatly saddened to hear of the passing earlier this week of two giants of hepatology, Prof. Wolfgang Gerok (1926–2021) and Prof. Roberto Groszmann (1939–2021).…
About EASL and the ALIVER Consortium The ALIVER Consortium of 11 institutions from seven European countries developed an innovative liver dialysis machine called Dialive™. This device helps the liver to regenerate naturally or, when that does not prove possible, keeps…
This year has been unlike any other. COVID-19 brought unimaginable challenges to the medical community, placing you at the forefront of the pandemic. The year 2020 posed unique questions to those of us treating liver patients and focusing on liver diseases. …
Are you deeply engaged in both hepatology and science and ready to get involved in EASL’s governance? EASL is now calling for nomination of two new Scientific Committee members to join the Governing Board. The term for these members is from the International Liver Congress (ILC) 2021 (end-June 2021) to ILC 2024. Please note: …